TCR-NF-κB signaling activates the SENP1-NR4A1 axis to fine-tune effector activation of CD8+ T cells
Cell Reports · 2026-03 · 45 (3) · 117102
DOI: 10.1016/j.celrep.2026.117102 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell Reports, 2026-03. Verfasst von Cen Jiang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai Key Laboratory for Tumor Microenvironment and Inflammation, Department of Biochemistry and Molecular Cell Biology, Shanghai Jiao Tong Univer…. Hauptthemen laut MEDLINE: Signal Transduction, CD8-Positive T-Lymphocytes, Nuclear Receptor Subfamily 4, Group A, Member 1, NF-kappa B. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
T cell receptor (TCR) signaling plays a crucial role in T cell activation by creating a negative controlling mechanism to limit the strength of immune activation; however, the underlying mechanisms remain to be fully elucidated. Here, we identify the small ubiquitin-like modifier (SUMO)-specific protease 1 (SENP1) as a target of the TCR-NF-κB signaling pathway that negatively regulates TCR-induced CD8+ T cell activation. SENP1 deficiency promotes the early occurrence of TCR-induced CD8+ T cell proliferation and effector gene expression. Mechanistically, the nuclear receptor NR4A1 is identified as a deSUMOylation target of SENP1 during this process. SENP1-mediated deSUMOylation of NR4A1 enhances its suppressive effect on the expression of TCR-induced effector genes in CD8+ T cells. Deficiency in the SENP1-NR4A1 axis markedly enhances the CD8+ T cell response against L. monocytogenes infection. Collectively, these findings identify SENP1 as a crucial regulator that integrates TCR-NF-κB signaling with NR4A1 activity to fine-tune the CD8+ T cell-mediated immune response.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Shanghai Key Laboratory for Tumor Microenvironment and Inflammation, Department of Biochemistry and Molecular Cell Biology, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Shanghai Key Laboratory for Tumor Microenvironment and Inflammation, Department of Biochemistry and Molecular Cell Biology, Shanghai Jiao Tong University School of Medicine, Shanghai, China; Department of Urology, Renji…
- Shanghai Institute of Immunology, Department of Immunology and Microbiology, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Institute of Biophysics, Chinese Academy of Sciences, Beijing, China.
- Shanghai Key Laboratory for Tumor Microenvironment and Inflammation, Department of Biochemistry and Molecular Cell Biology, Shanghai Jiao Tong University School of Medicine, Shanghai, China. Electronic address: jianlihe…
- Shanghai Key Laboratory for Tumor Microenvironment and Inflammation, Department of Biochemistry and Molecular Cell Biology, Shanghai Jiao Tong University School of Medicine, Shanghai, China; Hainan Medical University, H…
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Jiang, C., Yang, Y., Tian, J., Liang, Z., Fan, Q., Wang, Q., Shen, L., Wang, S., He, J., & Cheng, J. (2026). TCR-NF-κB signaling activates the SENP1-NR4A1 axis to fine-tune effector activation of CD8+ T cells. Cell Reports, 45(3), 117102. https://doi.org/10.1016/j.celrep.2026.117102
Vancouver
Jiang C, Yang Y, Tian J, Liang Z, Fan Q, Wang Q, et al. TCR-NF-κB signaling activates the SENP1-NR4A1 axis to fine-tune effector activation of CD8+ T cells. Cell Reports. 2026;45(3):117102. doi:10.1016/j.celrep.2026.117102
BibTeX
@article{Jiang2026,
author = {Jiang, Cen and Yang, Yuquan and Tian, Jing and Liang, Zi and Fan, Qiuju and Wang, Qi and Shen, Lei and Wang, Shengdian and He, Jianli and Cheng, Jinke},
title = {TCR-NF-κB signaling activates the SENP1-NR4A1 axis to fine-tune effector activation of CD8+ T cells},
journal = {Cell Reports},
year = {2026},
volume = {45},
number = {3},
pages = {117102},
doi = {10.1016/j.celrep.2026.117102}
}
EUVIMED